Clinical Trial Update: A Study of Idelalisib (GS1101, CAL101) + Ofatumumab in Previously Untreated CLL/SLL [Phase 2]

View source ↗

Summary

Phase 2 study evaluating idelalisib plus ofatumumab in previously untreated chronic lymphocytic leukemia and small lymphocytic lymphoma; the trial is completed …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Lymphocytic Leukemia
• Small Lymphocytic Lymphoma

Drugs mentioned

• Arzerra (ofatumumab)
• Zydelig (idelalisib)

Snippet

Sponsor: Dana-Farber Cancer Institute | Conditions: Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma | Phase 2 | Status: COMPLETED | Results posted: 2024-10-16